-
Mashup Score: 39Treatment Algorithm for Hepatocellular Carcinoma - 1 month(s) ago
Tanios S. Bekaii-Saab, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with hepatocellular carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 39Treatment Algorithm for Hepatocellular Carcinoma - 1 month(s) ago
Tanios S. Bekaii-Saab, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with hepatocellular carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 39Treatment Algorithm for Hepatocellular Carcinoma - 1 month(s) ago
Tanios S. Bekaii-Saab, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with hepatocellular carcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 22024 Upstate Cancer Symposium - About - Integrity CE - 1 month(s) ago
About Agenda Faculty Hotel Exhibitors COVID-19 Contact Attend In-Person or Virtually! Saturday, June 29, 2024 – Sunday, June 30, 2024 Register Now AGENDA Saturday, June 29, 2024, 8:00 AM – 5:00 PM EST Sunday, June 30, 2024, 7:30 AM – 3:00 PM EST Click here to view full program agenda Moderated by the Oncology Brothers: […]
Source: integrityce.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 23EV-302: Enfortumab Vedotin and Pembrolizumab - 1 month(s) ago
Thomas Powles, MBBS, MRCP, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the EV-302 study and the role of enfortumab vedotin plus pembrolizumab in the bladder cancer treatment landscape.
Source: www.targetedonc.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 43Bladder Cancer Treatment Algorithm - 2 month(s) ago
Karine Tawagi, MD, and Sia Daneshmand, MD, join the Oncology Brothers, Rahul Gosain, MD; and Rohit Gosain, MD, to discuss bladder cancer treatment algorithms.
Source: www.cancernetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 212024 Upstate Cancer Symposium - About - Integrity CE - 2 month(s) ago
About Agenda Speakers Hotel Exhibitors COVID-19 Contact Attend In-Person or Virtually! Saturday, June 29, 2024 – Sunday, June 30, 2024 Register Now AGENDA Saturday, June 29, 2024, 8:00 AM – 5:00 PM EST Sunday, June 30, 2024, 7:30 AM – 3:00 PM EST Click here to view full program agenda HOSTED BY Moderated by the […]
Source: integrityce.comCategories: General Medicine News, Partners & KOLsTweet-
We are thrilled about our first Upstate NY Cancer Symposium in June 2024! 1.5 days to focus and discuss SoC on the most commonly treated solid tumors and hematologic malignancies. Register at https://t.co/49Vv9pRr5D #OncTwitter #CME #HemeTwitter @WilmotCancer @RoswellPark https://t.co/0sV6FWfH6r https://t.co/gzBMMBETe8
-
-
Mashup Score: 42Kidney Cancer Treatment Algorithm - 2 month(s) ago
Sumanta Kumar Pal, MD, FASCO, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the treatment of patients with kidney cancer and highlight the evolving therapeutic landscape.
Source: www.cancernetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 7Kidney Cancer Treatment Algorithm - 2 month(s) ago
Sumanta Kumar Pal, MD, FASCO, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the treatment of patients with kidney cancer and highlight the evolving therapeutic landscape.
Source: www.cancernetwork.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 35Results from Study of Pembrolizumab in Muscle-invasive and Locally Advanced Urothelial Carcinoma - 2 month(s) ago
Get the results from the AMBASSADOR study presented by Dr. Andrea Apolo from the National Cancer Institute at ASCO GU 2024 in this MEDtalk. The study is a multi-center phase III trial investigating the efficacy of adjuvant pembrolizumab versus observation in patients with muscle-invasive urothelial carcinoma. Notably, disease-free survival extended to a median of 29 months compared to 14 months in the control group. Despite the overall survival data still maturing, this study paves the way for pembrolizumab as a potential treatment option for patients post-radical surgery and elaborates on the prognostic role of PD-L1 status and how it shapes treatment decisions within this patient demographic.
Source: bpno.dkCategories: General Medicine News, Partners & KOLsTweet
GI Series: #HCC algorithm, w/ @GIcancerDoc to reiterate the current landscape: Full Discussion: - https://t.co/1YGN2F23Bg - https://t.co/MF0Jm7BIA7 -Also on the “Oncology Brothers” podcast -🗣️ @aparna1024 & @KlempnerSam to follow. #OncTwitter @CancerNetwrk #MedTwitter #GISM https://t.co/MQj0pVTs0G